Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial).

MLA

Kosugi, Chihiro, et al. “Randomized Phase II Study of Tegafur–uracil/Leucovorin versus Tegafur–uracil/Leucovorin plus Oxaliplatin after Curative Resection of High-Risk Stage II/III Colorectal Cancer (SOAC-1101 Trial).” International Journal of Colorectal Disease, vol. 36, no. 8, Aug. 2021, pp. 1739–49. EBSCOhost, https://doi.org/10.1007/s00384-021-03906-w.

APA

Kosugi, C., Koda, K., Takiguchi, N., Takaishi, S., Miyauchi, H., Hirayama, N., Nomura, Y., Kondo, E., Kawasaki, Y., Ozawa, Y., & Matsubara, H. (2021). Randomized phase II study of tegafur–uracil/leucovorin versus tegafur–uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial). International Journal of Colorectal Disease, 36(8), 1739–1749. https://doi.org/10.1007/s00384-021-03906-w

Chicago

Kosugi, Chihiro, Keiji Koda, Nobuhiro Takiguchi, Satoru Takaishi, Hideaki Miyauchi, Nobuo Hirayama, Yukihiro Nomura, et al. 2021. “Randomized Phase II Study of Tegafur–uracil/Leucovorin versus Tegafur–uracil/Leucovorin plus Oxaliplatin after Curative Resection of High-Risk Stage II/III Colorectal Cancer (SOAC-1101 Trial).” International Journal of Colorectal Disease 36 (8): 1739–49. doi:10.1007/s00384-021-03906-w.